Immunotherapeutic efficacy of Th1 stimulatory epitopes derived from Leishmania donovani enolase and triose phosphatase isomerase in experimental visceral leishmaniasis
- 9 May 2025
- journal article
- Published by Elsevier in Molecular Immunology
- Vol. 183, 104-114
Abstract
No abstract availableKeywords
Funding Information
- Department of Science and Technology (JBR/2021/ 000010)
This publication has 48 references indexed in Scilit:
- New approaches to understanding the immune response to vaccination and infectionVaccine, 2015
- The differential expression of IL-4 and IL-13 and its impact on type-2 immunityCytokine, 2015
- Immunity to Leishmania and the rational search for vaccines against canine leishmaniasisTrends in Parasitology, 2010
- First generation leishmaniasis vaccines: A review of field efficacy trialsVaccine, 2008
- Th1-stimulatory polyproteins of soluble Leishmania donovani promastigotes ranging from 89.9 to 97.1kDa offers long-lasting protection against experimental visceral leishmaniasisVaccine, 2008
- Proteomic approach for identification and characterization of novel immunostimulatory proteins from soluble antigens of Leishmania donovani promastigotesProteomics, 2007
- Leishmania donovani: Identification of stimulatory soluble antigenic proteins using cured human and hamster lymphocytes for their prophylactic potential against visceral leishmaniasisVaccine, 2006
- Refractoriness to the treatment of sodium stibogluconate in Indian kala-azar field isolates persist in in vitro and in vivo experimental modelsParasitology Research, 2005
- Requirements for Th1-dependent immunity against infection with Leishmania majorMicrobes and Infection, 2004
- Effective immunotherapy against canine visceral leishmaniasis with the FML-vaccineVaccine, 2004